Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

NCT00733850 is registered in ClinicalTrials.gov with KangLaiTe USA as lead sponsor.

NCT NCT00733850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Lead sponsor
KangLaiTe USA
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
June 30, 2014
Enrollment
85 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer